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Abstract
High-throughput microarray and sequencing technology have been used to identify disease subtypes
that could not be observed otherwise by using clinical variables alone. The classical unsupervised
clustering strategy concerns primarily the identification of subpopulations that have similar patterns
in gene features. However, as the features corresponding to irrelevant confounders (e.g. gender or
age) may dominate the clustering process, the resulting clusters may or may not capture clinically
meaningful disease subtypes. This gives rise to a fundamental problem: can we find a subtyping pro-
cedure guided by a pre-specified disease outcome? Existing methods, such as supervised clustering,
apply a two-stage approach and depend on an arbitrary number of selected features associated with
outcome. In this paper, we propose a unified latent generative model to perform outcome-guided
disease subtyping constructed from omics data, which improves the resulting subtypes concerning
the disease of interest. Feature selection is embedded in a regularization regression. A modified EM
algorithm is applied for numerical computation and parameter estimation. The proposed method
performs feature selection, latent subtype characterization and outcome prediction simultaneously.
To account for possible outliers or violation of mixture Gaussian assumption, we incorporate robust
estimation using adaptive Huber or median-truncated loss function. Extensive simulations and an
application to complex lung diseases with transcriptomic and clinical data demonstrate the ability
of the proposed method to identify clinically relevant disease subtypes and signature genes suitable
to explore toward precision medicine.
Keywords: omics cluster analysis; cluster analysis; disease subtyping; variable selection; outcome
association; precision medicine.
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1. INTRODUCTION
Many complex diseases were once considered a single disorder, within which all patients receive a
uniform screening, diagnosis and treatment strategy. With better understanding of the underlying
disease mechanisms, evidences have emerged to define novel subtypes of many complex diseases
using clinical variables, selected biomarkers, imaging measurements, molecular profiling or genetic
alterations, where the therapeutic plan can be tailored to each subtype to improve disease prognosis.
In breast cancer, for example, four intrinsic subtypes (Lumina A, Lumina B, HER2-enriched and
Basal-like) and a Normal Breast-like group were first identified in Perou et al. (2000) by cluster
analysis of 42 patients based on microarray expression profile of 8102 genes and the result has
been validated in many follow-up studies. Of the subtypes, Lumina A and Lumina B patients
tend to have longer survival and lower recurrence rate, which require less aggressive treatment
to reduce side effects. Basal-like (triple negative) tumors are often more malignant and have a
poorer prognosis but can be successfully treated with certain combination of surgery, radiotherapy
and chemotherapy. HER2-enriched patients can be treated with HER2-targeted therapy such as
trastuzumab, which is surprisingly harmful to those in the Lumina subtypes. Subsequent tailored
screening/prevention programs and novel treatment strategies from successful disease subtyping
have decreased breast cancer mortality over the years (Jemal et al., 2009). Cluster analysis in
high-dimensional omics data to characterize novel disease subtypes is an essential first step towards
precision medicine and is the focus of this paper.
Classical clustering methods, such as hierarchical clustering, K-means clustering and Gaussian
mixture model, have been widely used in the literature for disease subtyping. These methods are
effective when the dimension of features is low and the clusters are well separated. The clustering
task, however, becomes more challenging in high-dimensional omics data (e.g. thousands of genes
in transcriptomic data) and the classical methods often fail to identify clinically meaningful clusters
since they naively treat all features as equally important. Similar to most small-n-large-p problems,
it is generally believed that only a small portion of features are relevant in the cluster character-
ization. A large amount of work has been devoted to dimension reduction and feature selection
in cluster analysis, such as sparse principal component analysis or sparse factor analysis coupled
with standard clustering (Zou et al., 2006; Bair et al., 2006), model-based clustering with variable
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selection (Tadesse et al., 2005; Pan and Shen, 2007) and sparse K-means (Witten and Tibshirani,
2010). Interested readers may refer to Bouveyron and Brunet-Saumard (2014) for further reference.
Although the aforementioned methods are powerful to simultaneously identify clusters and rel-
evant features, the resulting clusters of patients may not guarantee biological meaning or clinical
impact. A common practice is to perform post-hoc analyses to assess association between the iden-
tified clusters and disease relevant measures or clinical outcomes, such as survival. Such association
justifies potential clinical relevance of the novel disease subtypes and supports further investigation.
However, if no association is observed, the cluster analysis is considered a failed effort to bring clini-
cal impact. In the clustering of high-dimensional omics data, the latter situation happens frequently
since decision of final clusters largely depends on the selected features. The data may contain multi-
faceted cluster structures that can be defined by different sets of gene features. In Figure 1, we
demonstrate this phenomenon using a lung disease transcriptomic dataset. When we select the
top 50 X/Y chromosome genes (annotated in the GeneCards database; www.genecards.org) that
are most associated with the gender variable and perform simple K-means, Figure 1A identifies
two clear male/female clusters. Similarly, if the top 50 genes associated with the age variable are
selected from age-related genes annotated in the HAGR database (Tacutu et al., 2018), Figure 1B
finds three clusters of young, middle-aged and old patients through K-means clustering. Although
heatmaps in Figures 1A and 1B show well-separated clusters, they are not novel for the clinical
purpose of disease subtyping. Figure 1C shows result of the proposed outcome-guided clustering
method to be introduced. With guidance from the clinical outcome FEV1 (measuring the volume
of air a person can exhale during the first second of forced expiration), three clusters of patients
are identified with distinct clinical behavior and molecular mechanisms (see Section 4 for detailed
result). When gene signals are largely driven by potentially disease-irrelevant factors (e.g., as in
Figures 1A and 1B), genes that are directly relevant to the disease with greater clinical potential
(e.g. Figure 1C) are less likely to be uncovered. In the literature, constraints in the forms of prior
knowledge in samples (Wagstaff et al., 2001) or pathway structure in features (Huo and Tseng,
2017) have been used to restrict the free parameters in high-dimensional space during cluster-
ing. The approaches improve biological relevance of the finding, but still cannot prevent the true
outcome-associated disease subtypes from being masked by disease-irrelevant clusters.
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This practical example raises a fundamental question in clustering of high-dimensional omics
data for disease subtyping: can we simultaneously identify disease subtypes and the driving gene
signatures, where the detection of disease subtypes is guided by outcome association? This question
is unique as it touches both supervised and unsupervised components in the context of machine
learning. In the process of detecting novel disease subtypes, we focus on identifying disease-related
subtypes and hope to disentangle and reduce impact of factors driven by clinically irrelevant vari-
ables (e.g. demographic variables, such as gender, age and race). In the literature, little has been
done in this proposed direction. Bair and Tibshirani (2004) and Koestler et al. (2010) have devel-
oped a two-stage semi-supervised method, where K-means or other standard clustering methods
are applied to the top M features with the highest marginal outcome association. The two-stage
Samples Samples
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FEV1 FEV1 FEV1
Gender
Age
Gender
B
Age
Gender
Age
Figure 1: A real example illustrates (A) two gender-associated clusters are found by the top 50
X/Y chromosome genes and K-means; (B) three age-associated clusters are detected by the top
50 age-related genes and K-means; (C) three clusters are identified from our algorithm, which are
associated with clinical outcome FEV1 but neither associated with gender nor age.
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approach is, however, ad hoc in selecting the number of top features M and has difficulty in incor-
porating confounding variables in the outcome association. In this paper, we propose an outcome-
guided clustering (ogClust) model to provide a unified solution. To the best of our knowledge,
the proposed method is the first unified generative model for outcome-guided disease subtyping
(clustering).
Throughout this paper, we avoid the term “semi-supervised” adopted by Bair and Tibshirani
(2004) and Koestler et al. (2010). Instead, we name by “outcome-guided disease subtyping” or
“outcome-guided clustering” since the term “semi-supervised learning” has been used in at least two
other machine learning scenarios: (1) A small set of labeled data and a larger set of unlabeled data
are jointly analyzed for machine learning; (2) Cluster analysis is pursued with known constraints
(e.g. pairs of observation must or must not be clustered together). Interested readers may refer
to Bair (2013) for a review of semi-supervised clustering methods. One should also note that the
outcome-guided clustering discussed in this paper substantially differs from latent class analysis
methods in regression setting by Houseman et al. (2006), DeSantis et al. (2007) and Desantis et al.
(2012). In this case, patients in latent classes are identified to have heterogeneous intercepts or
regression slopes. The latent classes, in a sense, represent patient clusters (or disease subtypes),
but there is lack of a gene signature and prediction model to classify future patients into the disease
subtypes (latent classes), presenting a major obstacle towards precision medicine.
The paper is structured as follows. Section 2 introduces the ogClust model (Section 2.1, an EM
algorithm for parameter estimation (Section 2.2), extensions to robust estimation procedures in
outcome association (Section 2.3), and its extension to survival outcome (Section 2.4). We perform
extensive simulations to evaluate ogClust and compare it with existing methods in Section 3.1, and
evaluate its robust estimation in Section 3.2. A disease subtyping application using a lung disease
transcriptomic dataset is presented in Section 4. We include final conclusion and discussion in
Section 5.
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2. OUTCOME-GUIDED CLUSTERING MODEL
2.1 Model and Notations
We consider the problem of disease subtyping (clustering) of n observations from high-dimensional
data G = {gij , 1 ≤ i ≤ n, 1 ≤ j ≤ q}, where G can be mRNA expression, miRNA expression,
methylation or phenomic data and q can be at the scale of hundreds to thousands. Our ultimate
goal is to cluster n observations into K clinically meaningful clusters represented by latent group
label Z = {zi, 1 ≤ i ≤ n}, zi ∈ {1, . . . ,K}, and zi = k means that observation i is assigned to
cluster k (1 ≤ k ≤ K). Since clustering result purely from G may not necessarily be clinically
useful as discussed in Section 1, we assume that a clinical outcome Y = {yi, 1 ≤ i ≤ n} is given to
guide the clustering (e.g. survival outcome or FEV1%prd in the lung disease example in Section
4). We also assume a set of pre-specified covariates X = {xij , 1 ≤ i ≤ n, 1 ≤ j ≤ p}, where the p
covariates (e.g. age, gender, etc.) are potentially associated with the outcome and may confound
with the association between Z and Y . Denote by gi = (gi1, . . . , giq)
T and xi = (xi1, . . . , xip)
T .
We assume observed data (yi,xi, gi) for subject i (1 ≤ i ≤ n) are independent realizations of the
model for (Y,X,G).
As shown in Figure 2, the proposed ogClust framework consists of two components: disease
subtyping model and outcome association model. The disease subtyping model is a conventional
high-dimensional discriminant analysis where we train to characterize pik = Pr(Z = k|G) (or
piik = Pr(Zi = k|gi) for observation i). In this paper, we apply a multinomial logistic regression
piik|γ = exp(g
T
i γk)∑K
l=1 exp(gTi γl)
, where γ = {γk, 1 ≤ k ≤ K} and γk = (γ1k, . . . , γqk)T . Since q is usually
large, we assume only a small subset A ⊂ {1, . . . , q} of features effective in characterizing the
clusters that affect the outcome, where its cardinality card(A) < min(n, q). In other words, γ[j] 6= 0
if j ∈ A and γ[j] = 0 if j ∈ Ac, where γ[j] = {γj1, . . . , γjK}. We apply LASSO regularization,
or group LASSO regularization (Tibshirani et al., 2012) with parameters in γ[j] as a group to the
multinomial logistic regression to select subtyping features.
In the outcome association model, we assume the following mixture model:
f(yi;xi) =
K∑
k=1
piikfk(yi;xi), (1)
where fk(y;x) is density function of cluster k. We assume a continuous response Y where the
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k-th mixture density fk(y;x, β0k,β, σ) is parameterized by cluster specific intercept β0k, common
covariate effect β = (β1, . . . , βp)
T and a homogeneous error σ. In this paper, we specifically assume
yi|zi = k ∼ N(β0k + βTxi, σ2) with mixture probability piik = exp(g
T
i γk)∑K
l=1 exp(gTi γl)
, k = 1, . . . ,K.
Denote by θ = {β0,β,γ, σ} the collection of all parameters from the two models in ogClust
(β0 = (β01, . . . , β0K)
T ), given Y, X and G, θ can be estimated by maximizing the following sample
likelihood of the basic model:
L(θ) =
n∏
i=1
K∑
k=1
piik(gi,γ)f (yi;xi, β0k,β, σ) . (2)
Remarks:
1. Generalization from continuous outcome Y to other types of outcome Y is relatively straight-
forward. Section 2.4 discusses the extension to survival outcome.
2. In the current model, we assume only several important and pre-selected covariates for X and
no variable selection is implemented in the outcome association model. Including X (e.g. age or
Figure 2: A graphical illustration of the unified regression model. Y is the outcome to guide
clustering, X are the baseline covariates that are believed to have effects on Y. G are the variables
(e.g. gene expression) that defines the outcome associated subgroups. Z is the unobserved latent
subgroup index to define final clustering.
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gender) in outcome association has two main advantages: (i) it corrects for potential confounding
effects between the association of outcome Y and subtype Z, (ii) if a covariate, say, gender, is
indeed predictive of Y and there exist many strong gender-associated genes in G, the model
will avoid identification of gender-related clusters in Z. In this case, although gender-associated
subtypes are predictive of the outcome, their information has been captured by observable
covariate and thus can be avoided in subtyping.
3. The current model assumes a simplified common covariate effect β across all clusters. It is
straightforward to extend for cluster-specific interaction term βk, meaning cluster-specific age
or gender effects.
4. We apply multinomial logistic regression in this paper but other high-dimensional discriminant
analysis methods, such as sparse linear discriminant analysis, can also be used.
5. The conditional probability pˆiik|γˆ = exp(g
T
i γˆk)∑K
l=1 exp(gTi γˆl)
can be used to predict the cluster label of
new observations.
2.2 Numerical Solution with Gene selection
A numerical method using EM algorithm is proposed for ogClust parameter estimation in Eq.
(2). By introducing zik, k = 1, . . . ,K, as missing indicator variables, following the seminal idea in
Dempster et al. (1977), the complete log likelihood function can be written as
lcn(θ) =
n∑
i=1
K∑
k=1
{zik log piik + zik log f (yi;xi, β0k,β, σ)} , (3)
where zik = 1 if subject i belongs to subgroup k, and zik = 0 otherwise.
Since gene expression is usually high dimensional, including genes in Ac with non-predictive
effect will introduce extra noise to the disease subtyping model and may produce irrelevant subtypes
that are not necessarily related to the disease outcome of interest. In the following, we will illustrate
with a LASSO penalty or an alternative group LASSO regularization framework for gene selection.
We define the penalized log-likelihood function as
l˜cn(θ) =
n∑
i=1
K∑
k=1
{zik log piik + zik log f (yi;xi, β0k,β, σ)} − λR(γ), (4)
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where λ is the regularization tuning parameter and R(γ) =
∑q
j=1
∑K
k=1 |γjk| for LASSO penalty.
Alternatively, we can use group LASSO penalty plus `2 regularization R(γ) =
∑q
j=1 ‖γ[j]‖2 +
α
∑q
j=1
∑K
k=1 γ
2
jk, where ‖γ[j]‖2 =
√∑K
k=1 γ
2
jk. The first term is a group LASSO penalty to select
or deselect γ[j] for gene j. The second term encourages joint selection of predictive genes with high
collinearity. Detecting multiple genes with high collinearity offers better molecular insight to the
subtype mechanism and provides more stable cluster prediction for future patients. The irrelevant
features are removed by shrinking corresponding elements of γ[j] to zero, thus a sub-model is
automatically selected. This procedure performs feature selection and numerical estimation of
parameters simultaneously.
Maximization of l˜cn(θ) can be achieved by sequentially and iteratively updating β0, β, σ and γ
in an EM algorithm, which takes the following steps:
• The E step computes the conditional expectation of the function l˜cn(θ) with respect to zik,
given the observed data yi, xi and the current parameter estimates θ
(m),
Q
(
θ,θ(m)
)
=
n∑
i=1
K∑
k=1
w
(m)
ik log piik +
n∑
i=1
K∑
k=1
w
(m)
ik log f (yi;xi, β0k,β, σ)− λ
q∑
j=1
R(γj),
where the posterior weights
w
(m)
ik = E
(
Zik|yi,xi,θ(m)
)
=
pi
(m)
ik f
(
yi;xi, β
(m)
0k ,β
(m), σ(m)
)
∑K
l=1 pi
(m)
il f
(
yi;xi, β
(m)
0l ,β
(m), σ(m)
) . (5)
• The M step on the (m + 1)-th iteration maximizes the Q
(
θ,θ(m)
)
with respect to θ. By
taking partial derivative, it is easy to show that β0, β and σ
2 are updated by the following
updating equations:
β
(m+1)
0k =
∑n
i=1w
(m)
ik
(
yi − (β(m))Txi
)
∑n
i=1w
(m)
ik
, k = 1, . . . ,K, (6)
β
(m+1)
` =
∑n
i=1
∑K
k=1w
(m)
ik xi`
(
yi − β(m+1)0k −
∑
h6=` β
(m)
h xih
)
∑n
i=1
∑K
k=1w
(m)
ik x
2
i`
, ` = 1, . . . , p, (7)
(σ(m+1))2 =
∑n
i=1
∑K
k=1w
(m)
ik
(
yi − β(m+1)0k − (β(m+1))Txi
)2
∑n
i=1
∑K
k=1w
(m)
ik
. (8)
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The updated estimates γ(m+1) is obtained following an approximation procedure of Friedman
et al. (2010). For lasso penalty R(γ) =
∑K
k=1Rk(γk) =
∑K
k=1
∑q
j=1 |γjk|, the likelihood for
estimating γ(m+1) given w(m) is
l˜p
(
θ,θ(m)
)
=
n∑
i=1
K∑
k=1
w
(m)
ik log piik − λR(γ) =
n∑
i=1
K∑
k=1
w
(m)
ik log
exp
(
gTi γk
)∑K
l=1 exp
(
gTi γl
) − λR(γ)
=
n∑
i=1
K∑
k=1
w
(m)
ik
{
gTi γk − log
(
K∑
l=1
exp
(
gTi γl
))}− λR(γ) (9)
We approximate the partial log likelihood l˜p(θ,θ
(m)) by quadratic approximation. The re-
sulting partial likelihood l˜Qk(θ,θ
(m)) for subgroup k is in the form of a weighted least square:
l˜Qk
(
θ,θ(m)
)
= −1
2
n∑
i=1
Wik
(
hik − gTi γk
)2 − λRk(γk) + C,
where hik = g
T
i γ
(m)
k +
w
(m)
ik −pi
(m)
ik
Wik
, Wik = pi
(m)
ik (1− pi(m)ik ), and C is independent of γk. Thus
the solution to γ(m+1) can be obtained by coordinate descent, i.e., individually solving
maxγk∈Rq l˜Qk(θ,θ
(m)) for each k. By some algebraic manipulation, we obtain the estimate
γ˜kj =
S
(∑N
i=1 gijWik
(
hik − (g(j)i )T γ˜(j)k
)
, λ
)
∑N
i=1Wikg
2
ij
, (10)
where S(z, λ) = sign(z)(|z| − λ)+ is a soft thresholding operator, (a)+ = max(0, a), γ˜(j)k
is the parameter vector γ˜k omitting γ˜kj , and g
(j)
i is the gene vector gi omitting gij . The
coordinate descent procedure iteratively updates the current estimate γ˜ until convergence.
For the group LASSO + `2 regularization, we apply the glmnet function in R package glmnet,
setting multinomial family, grouped type and α equals 0.5.
The pseudo code for fitting the unified ogClust model is given in Algorithm 1. Multiple ini-
tials could be used to avoid convergence to local minimums and increase the numerical stability
of parameter estimates. We use Bayesian information criterion (BIC) to determine the tuning pa-
rameter λ and the number of subgroups K in simulation. BIC is defined as ln(n)df(θˆ)− 2 ln(L(θˆ)),
where θˆ = {βˆ0, βˆ, γˆ, σˆ} and df(θˆ) is the number of non-zero estimated parameters. In the real
application, because of potential data noises and violation of Gaussian assumption, BIC may fail
to choose the correct K. To address this issue, we plot the trend of RMSE and R2 as a function of
K and identify the elbow point as the optimal number of clusters K as shown in Figure S3.
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Algorithm 1 Pseudo code for ogClust model estimation.
input: Y, X, G and K
Initialize θ(0) and set m = 0;
repeat
E-step: compute the posterior weights w
(m)
ik by Equation (5);
M-step:
1. Update {β(m)0 ,β(m), σ(m)} to {β(m+1)0 ,β(m+1), σ(m+1)} by Equations (6)-(8);
2. Update γ(m) to γ(m+1) by coordinate descent:
Set γ˜old = γ(m);
repeat
Update γ˜oldkj to γ˜
new
kj by Equation (10), for k = 1, . . . ,K and j = 1, . . . , q;
until ||γ˜old − γ˜new|| < 10−7;
Set γ(m+1) = γ˜newkj , θ
(m+1) = {β(m+1)0 ,β(m+1),γ(m+1), σ(m+1)}, m = m+ 1;
until ||θ(m) − θ(m−1)|| < 10−7;
output: Parameter estimates θˆ = θ(m)
2.3 Robust Estimation Procedures
The ogClust model is based on and could be sensitive to the Gaussian mixture assumption in
outcome Y . There are three common types of model misspecification: (A) heavy-tailed or skewed
error term in the outcome association model, (B) outlier outcomes in the outcome association model,
and (C) scattered observations who do not fit into any of the K subtypes in the disease subtyping
model. Our model is relatively robust to type C noises because of the soft assignment using
multinomial logistic probability function. One may iteratively remove a small number of samples
with unconfident cluster assignment. To guard against the first two types of model misspecification,
we propose 1) ogClust with median-truncated loss (ogClust-median-truncation) 2) ogClust with
Huber loss (ogClust-Huber) 3) ogClust with adaptive-Huber loss (ogClust-adHuber) to replace the
original ogClust with quadratic loss. Intuitively, median-truncation and Huber loss functions are
effective in dealing with potential outliers. As we will introduce later, the adaptive-Huber loss is
particularly useful for heavy-tailed and skewed error terms. Hence, the penalized log-likelihood
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function is defined as
lcn(θ) =
n∑
i=1
K∑
k=1
{zik log piik + zik`τ (eik)} − λ
p∑
j=1
R(γj).
where `τ (eik) denotes the robust loss function to replace log f (yi;xi, β0k,β, σ). We follow the same
EM procedure with modified loss functions to compute numerical solutions.
Median-truncated Loss The median-truncated loss (Chi et al., 2019) describes the loss function for
subject i in subgroup k as:
`τ (eik) =
 e
2
ik/2 if |eik| ≤ τk
0 if |eik| > τk
,
where eik = yi − βˆ0k − βˆTXi, and τk = median {|eik|}ni=1. The loss function remains the same for
eik smaller or equal to median τk, and the loss function equals to 0 for eik larger than the median
τk. The cutoff τk is chosen as the median of e1k, ..., enk. By taking partial derivative, the estimates
in the (m+ 1)th iteration for β0, β and σ are obtained by the following equations:
β
(m+1)
0k =
∑n
i=1w
(m)
ik
(
yi − (β(m))Txi
)
I
(∣∣∣e(m)ik ∣∣∣ ≤ τk)∑n
i=1w
(m)
ik I
(∣∣∣e(m)ik ∣∣∣ ≤ τk) ,
β
(m+1)
` =
∑n
i=1
∑K
k=1w
(m)
ik xi`
(
yi − β(m+1)0k −
∑
h6=` β
(m)
h xih
)
I
(∣∣∣e(m)ik ∣∣∣ ≤ τk)∑n
i=1
∑K
k=1w
(m)
ik x
2
i`I
(∣∣∣e(m)ik ∣∣∣ ≤ τk) ,
(σ(m+1))2 =
∑n
i=1
∑K
k=1w
(m)
ik
(
yi − β(m+1)0k − (β(m+1))Txi
)2
I
(∣∣∣e(m)ik ∣∣∣ ≤ τk)∑n
i=1
∑K
k=1w
(m)
ik I
(∣∣∣e(m)ik ∣∣∣ ≤ τk) .
Huber Loss The Huber loss alternatively describes the loss function for subject i in subgroup k as:
`τ (eik) =
 e
2
ik/2 if |eik| ≤ τ
τ |eik| − τ2/2 if |eik| > τ
.
This loss function is quadratic for small values of e, and linear for large values of e. The cutoff τ
is suggested as a fixed constant (τ = 1.345) which gives 95% efficiency under Gaussian assumption
in regression setting (Huber, 2004). By EM algorithm, the estimates in the (m+ 1)th iteration for
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β0, β and σ
2 are obtained by the following equations:
β
(m+1)
0k =
∑n
i=1w
(m)
ik
(
yi − (β(m))Txi
)
I
(∣∣∣e(m)ik ∣∣∣ ≤ τ)+∑ni=1w(m)ik · τ · sign(e(m)ik ) · I (∣∣∣e(m)ik ∣∣∣ > τ)∑n
i=1w
(m)
ik I
(∣∣∣e(m)ik ∣∣∣ ≤ τ) ,
β
(m+1)
` =
∑n
i=1
∑K
k=1w
(m)
ik xi`
((
yi − β(m+1)0k −
∑
h6=` β
(m)
h xih
)
I
(∣∣∣e(m)ik ∣∣∣ ≤ τ))∑n
i=1
∑K
k=1w
(m)
ik x
2
i`I
(∣∣∣e(m)ik ∣∣∣ ≤ τ) +
τ sign
(
e
(m)
ik
)
I
(∣∣∣e(m)ik ∣∣∣ > τ)∑n
i=1
∑K
k=1w
(m)
ik x
2
i`I
(∣∣∣e(m)ik ∣∣∣ ≤ τ) ,
(σ(m+1))2 =
∑n
i=1
∑K
k=1w
(m)
ik
(
yi − β(m+1)0k − (β(m+1))Txi
)2
I
(∣∣∣e(m)ik ∣∣∣ ≤ τ)∑n
i=1
∑K
k=1w
(m)
ik I
(∣∣∣e(m)ik ∣∣∣ ≤ τ) +∑n
i=1
∑K
k=1w
(m)
ik
(
2τ
∣∣∣yi − β(m+1)0k −XTi β(m+1)∣∣∣− τ2) I (∣∣∣e(m)ik ∣∣∣ > τ)∑n
i=1
∑K
k=1w
(m)
ik I
(∣∣∣e(m)ik ∣∣∣ ≤ τ) .
Adaptive Huber Loss When there is no outlier but the error term is heavy-tailed asymmetric,
median-truncated loss or Huber loss using constant τ would introduces bias (Sun et al., 2019). To
mitigate this bias, we use an adaptive Huber loss in the EM algorithm by adopting the method of
Wang et al. (2020). In this method, the cutoff τ is data-driven and estimated adaptively, taking
into account sample size, n, dimension of β, p, by iteratively solving the following equations: g1(θ, τ) :=
∑n
i=1w
(m)
ik
∑K
k=1 `
′
τ (eik)Xi = 0
g2(θ, τ) := (n− p)−1
∑n
i=1
∑K
k=1 min
{
e2ik, τ
2
}
/τ2 − n−1(p+ z) = 0
,where z = log(n) by default. This method is implemented in R package tfHuber. We adapt it
into the M-step of our EM algorithm to update {β0,β, σ}. At a high level, by allowing increasing
value of cutoff τ as n increases, there is a trade-off between the robustness and bias. By picking
an optimal τ , the bias becomes negligible while the result is still robust to outliers caused by
heavy-tailed noises.
2.4 ogClust Model with Survival Outcome
ogClust model can be extended to use survival outcome. To facilitate model fitting, we choose
accelerated failure time (AFT) model with log-logistic distribution to model time-to-event data as
(log(Y )|Z = k) = β0k +Xβ+Wσ, where W ∼ standard logistic distribution and σ is the standard
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deviation. Therefore, the likelihood of mixture model can be written as
L(θ) =
n∏
i=1
K∑
k=1
piikLik (yi|xi, β0k,β, σk, ) .
Denote δ as a binary indicator of event, δ = 1 means event and 0 means right-censored. The
likelihood function Lik (Yi|xi, β0k,β, σ) is defined as
Lik (yi|xi, β0k,β, σ) =
{
1
σ
fW (wi)
}δi
{SW (wi)}1−δi
, where
wi =
zi − β0k −Xiβ
σ
SW (wi) = 1/ (1 + e
wi)
fW (wi) = e
wi/ (1 + ewi)2 .
Therefore, the penalized log-likelihood function is defined as:
l˜cn(θ) =
n∑
i=1
K∑
k=1
{zik log piik + ziklogLik (yi|xi, β0k,β, σ)} − λR(γ).
We follow the same EM algorithm in the original model, except that the likelihood of the ATF
model is maximized by implementing R package ”survival”.
3. NUMERICAL STUDIES
In this section, we conduct three simulations to evaluate the performance of clustering, feature
selection, and outcome prediction for ogClust, robust estimation procedures of ogClust, and its
extension for survival outcome respectively. In section 3.1 we assume that the continuous outcome
Y follows mixture of Gaussian distribution and compare the performance of ogClust with three
other methods. In section 3.2 we introduce outliers or skewed and heavy-tailed errors to outcome
Y , and compare the performance of three robust estimation procedures with the non-robust ogClust
method. In section 3.3 we show the advantage of ogClust over three other methods with survival
outcome Y to guide the clustering.
3.1 Simulations to Evaluate OgClust
Simulation scheme
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1. Simulate q = 1000 genes (G = {G1, ..., G1000}), among which G1 to G30 are differentially
expressed (DE) across clusters while the rest of the genes are noises and their expression
values are randomly drawn from the standard normal distribution (Figure S1B). Expression
levels of the 30 DE genes are randomly drawn from N(1,1) and N(0,1) to form 3 × 3 clusters
as specified in Figure S1A: gene set GA1 , A1 = {1, . . . , 15}, defines three clusters associated
with the outcome Y ; gene set GA2 , A2 = {16, . . . , 30}, defines three “clinically irrelevant
clusters” that are independent of Y .
2. Use parameters corresponding to A1, γA1 = (γ1A1 ,γ2A1 ,γ3A1)T , to represent the effect of
gene expression on subtyping. For identifiability, we set γ3A1 = 0. γ1A1 and γ2A1 vary in
different models. The active set for outcome-guided subtypes is restricted to A1, in other
words, γAc1 = 0.
3. Given gene expression ofGA1 and γA1 , we obtain piik =
exp(gTiA1γkA1 )∑3
l=1 exp(g
T
iA1γlA1 )
, k ∈ {1, 2, 3}, which
represent the probability of subject i belonging to the kth subgroup. Therefore, subgroup
indicator Zi for subject i is randomly drawn from a multinomial distribution with probability
pi = (pii1, pii2, pii3)
4. Sample independent covariates X1 and X2 are sampled from normal distributions N(1, 1) and
N(2, 1) respectively. Recall that β = (β1, β2)
T is the set of regression coefficients of the two
covariates and β0 = (β01, β02, β03)
T represents the baseline mean of the three subgroups. We
set β = (1, 1)T , and β0 varies according to different models.
5. Given the latent subgroup index Zi, the outcome for subject i can be simulated by (Yi|Zi =
k) = β0k +X
T
i β + ei, where ei ∼ N(0, σ2) and we set σ2 = 1.
The simulation scheme is illustrated in detail in Figure S1. Let β0 = (1, 1+δ, 1+2δ)
T and γA1 =
((rep(γ, 5), rep(0, 5), rep(-γ, 5))T , (rep(-γ, 5), rep(0, 5), rep(γ, 5))T , (rep(0, 15))T ), where rep(a, b) =
(a, . . . , a)(1×b). We consider four models with different choices of β0 and γA1 specified below:
• Model 1: γ = 1 and δ = 2
• Model 2: γ = 1 and δ = 3
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• Model 3: γ = 1 and δ = 5
• Model 4: γ = 3 and δ = 3
Essentially, γ controls the level of cluster separation in the omics space and δ represents the strength
of outcome association of the clusters. We first evaluate Models 1-3 with lower level of cluster
separation γ = 1 and varying outcome association δ = 2, 3, 5. Model 4 evaluates γ = δ = 3.
We compare the performance of the proposed ogClust using group LASSO + `2 penalty with
three other competing clustering methods: 1) SKM: sparse K-means clustering (Witten and Tib-
shirani, 2010), a modified K-means algorithm with variable selection; 2) PMBC: penalized model
based clustering (Pan and Shen, 2007), an unsupervised method based on Gaussian mixture model;
3) SC: supervised clustering (Bair and Tibshirani, 2004), a post-screening clustering method. SKM
and PMBC are not outcome-guided and could be sensitive to any “clinically irrelevant” clusters,
while SC has a variable pre-screening by outcome association. To evaluate the performance of these
methods, we simulate 100 datasets with sample size n = 600, where there are 1000 genes and three
subgroups with equal size. To implement SKM and PMBC and compare with ogClust, we assign
observations to the cluster with closest center (SKM) or with the highest posterior probability
(PMBC), then fit linear regression with covariate X and outcome Y in each resulting cluster to
make outcome prediction. For SC, we apply a pre-screen step to pre-select M outcome associated
genes before we perform K-means clustering and fit linear regression in each resulting cluster, the
value of M is determined by cross-validation.
The performance of these methods is evaluated by their clustering accuracy, gene selection and
outcome prediction by 10-fold cross-validation. Within each fold of training/testing split, we fit
each of the methods using the training set and then predict both latent subgroup label and outcome
value for testing set. We compute RMSE =
√∑n
i=1(yi − yˆi)2/n and R2 = 1−SSresidual/SStotal =
1−
∑n
i=1(yi−yˆi)2∑n
i=1(yi−yi)2
from the 10-fold cross validation and average the results to measure the prediction
error of outcome (Table 1). We also compute the average number of false positives (FPs) and false
negatives (FNs) for evaluating the accuracy of feature selection (Table 1). For clustering accuracy,
we compute the adjusted Rand index (ARI) (Hubert and Arabie, 1985), which has 0 expectation
when clustering is random and bounded by 1 with perfect partition, to measure the consistency of
predicted subgroup label with true latent subgroup index (Table 1).
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Table 1 shows results of ogClust compared to SKM, PMBC and SC under the four simulation
settings. To measure clustering performance, PMBC and SKM identifies K = 3 clusters in 100 and
37-38 of the 100 simulations but since the algorithm has no outcome guidance, they mostly obtain
clinically irrelevant clusters and have ARI= 0.04-0.16 when compared with the three true outcome-
associated clusters. SC pre-selects outcome-associated gene features to perform clustering and
generates improved ARI=0.35-0.41, but the method identifies K = 2 clusters for all simulations. In
contrast, ogClust identifies K = 3 clusters for 98-99 out of 100 simulations and produces ARI=0.86-
0.91 for Model 2-4. For the weak signal Model 1, ogClust identifies K = 3 clusters for 37 of the 100
simulations and the ARI reduces to 0.45. When evaluating gene selection, PMBC misses majority of
the first 15 true clustering genes (8.7-11.1 FNs) and both SKM and PMBC add many false positives
(776.1-813.8 FPs for SKM and 87.0-100.3 FPs for PMBC). SC contains outcome association gene
selection but still misses 4.8-8.7 FNs and adds 17.5-88.0 FPs. In contrast, ogClust almost does
not miss true clustering genes (FN=0 for Model 2-4 and FN=3 for Model 1) and only adds ∼14
false positives. For outcome prediction result, ogClust generates the lowest RMSE and the highest
R2, showing better clinical relevance of produced disease subtypes. In summary, SKM and PMBC
are vulnerable to miss clinically relevant clusters and related predictive genes. SC only modestly
improves in detecting outcome-associated genes and clusters, and the two-stage approach reduces
performance and rigor of inference. ogClust outperforms the three methods in clustering accuracy,
gene selection and clinical outcome prediction.
Table S1 and S2 show the simulation results when there is a stronger and weaker signal in
GA2 compared with GA1 respectively. When the signal in GA2 is stronger, SKM and PMBC
are dominated by GA2 and returns clinically irrelevant clusters with ARI=0. When the signal in
GA2 is weaker, SKM and PMBC performs slightly better in identifying the three outcome associated
clusters and outcome prediction with higher ARI and R2. However, the expression of GA2 has little
influence on the performance of SC and ogClust. Overall, ogClust performs consistently the best
among all the simulation settings.
3.2 Robust Estimation under Outliers or Heavy-tailed Errors
To compare the performance of robust methods in guarding against outliers or violation of Gaussian
mixture assumption, we perform simulation in the following settings:
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Table 1: Comparison of sparse K-means (SKM), penalized model based clustering (PMBC), super-
vised clustering (SC) and outcome-guided clustering (ogClust) under four simulation model settings
with 600 observations and 2 baseline covariates, 1000 genes and 100 repetitions.
Methods Estimated K ARI Selected Genes Outcome
2 3 > 3 FPs FNs RMSE R2
Model 1: γ = 1; δ = 2
SKM 100 0 0 0.04 776.1 1.9 1.93 0.25
PMBC 82 6 12 0.08 88.0 11.1 1.93 0.24
SC 100 0 0 0.35 41.3 4.8 1.58 0.48
ogClust 62 37 1 0.45 5.9 3.0 1.55 0.51
Model 2: γ = 1; δ = 3
SKM 100 0 0 0.04 776.1 1.9 2.65 0.15
PMBC 82 11 7 0.10 87.0 10.2 2.67 0.14
SC 100 0 0 0.36 33.4 4.9 2.08 0.47
ogClust 2 98 0 0.86 14.6 0.0 1.90 0.56
Model 3: γ = 1; δ = 5
SKM 100 0 0 0.04 776.1 1.9 4.20 0.05
PMBC 74 11 15 0.09 100.3 10.2 4.22 0.05
SC 100 0 0 0.36 37.9 4.9 3.20 0.46
ogClust 0 99 1 0.91 14.5 0.0 2.70 0.61
Model 4: γ = 3; δ = 3
SKM 100 0 0 0.05 813.8 1.6 2.61 0.15
PMBC 83 5 12 0.16 96.7 8.7 2.64 0.15
SC 100 0 0 0.41 17.5 5.0 2.01 0.48
ogClust 1 99 0 0.88 12.0 0.0 1.75 0.63
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• Setting A: The error term in the outcome association model is randomly drawn from standard
normal distribution; normal assumption is not violated.
• Setting B: 10% of the observations are outliers and the error term is randomly drawn from
unif(min-10,max+10).
• Setting C: The error term is randomly drawn from heavy-tailed lognormal distribution with
log-mean 0 and log-standard deviation 1.
The simulation scheme follows Model 2 in Section 3.1, except that in step 5, the generation of
outcome Y varies according to the different settings above. Under each setting, we compare the
performance of ogClust, ogClust-Huber, ogClust-adHuber, and ogClust-median-truncation. Models
are fit in the training data and tested in the testing data where four measures, i.e. RMSE, R2,
ARI and FNs, are calculated. We tune the number of selected genes by altering the parameter λ.
The analysis above is performed on 100 sets of training and testing data such that we can obtained
smooth curves capturing the trend of the four measures against the varying number of selected
genes.
As shown in Figure 3, in the first column when the normal assumption is satisfied, the non-
robust ogClust model performs the best and the three robust methods have only very slightly worse
performance. This shows that robust estimation methods only minimally reduce efficiency when
Gaussian mixture assumption is true. On the other hand, when Gaussian assumption is violated in
the second and the third columns, the three robust methods greatly outperform the original model.
ogClust-adHuber consistently outperforms ogClust-Huber with fixed cutoff. Compared to median
truncation, ogClust-adHuber performs better for heavy-tailed error term but slightly worse with
existence of outliers. ogClust-median-truncation can quickly capture the outcome associated DE
genes with relatively low number of selected genes, but it performs worse than ogClust-adHuber in
setting C because of the bias in parameter estimates. Since ogClust-adHuber outperforms ogClust-
huber overall and performs well in most settings, it is recommended for general applications and
will be evaluated in real data in Section 4.
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Figure 3: Comparison of ogClust and three robust ogClust methods under settings A: error term is
randomly drawn from standard normal distribution, setting B: 10% of the observations are outliers,
and setting C: error term is randomly drawn from heavy-tailed lognormal distribution. We compare
RMSE, R2, ARI and FNs (y-axis) vs number of genes selected in each setting (x-axis).
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3.3 Simulation to Evaluate ogClust for Survival Outcome
The simulation scheme is the same as in Section 3.1, except that in step 5, survival outcome is
generated as follows: given subgroup index Z, survival time Y follows AFT model with log-logistic
distribution, i.e. (log(Y )|Z = k) = β0k + Xβ + Wσ, where W ∼ standard logistic distribution
and σ = 0.5. We set the end of follow-up time to be 100, any time that is greater than 100 is
right-censored.
We evaluate the performance under four settings: (A) γ = 1 and δ = 1, (B) γ = 3 and δ = 1,
(C) γ = 1 and δ = 2, and (D) γ = 3 and δ = 2, representing varying level of cluster separation
(reflected by γ) and outcome association (δ). Similar to Section 3.2, we compare the performance
of SKM, PMBC, SC and ogClust in terms of RMSE, R2, ARI and FNs under each setting. Models
are evaluated in 100 sets of simulated training and testing data. We vary the number of selected
genes by tuning the penalty parameter λ and obtain smooth curves representing the trend of the
four measures against the varying number of selected genes.
As the result shown in Figure S2, SKM and PMBC have the lowest ARI, highest RMSE, lowest
R2 and highest FNs among all four settings because they lack outcome guidance. SC has improved
the four measures when compared with SKM and PMBC, and ogClust consistently outperforms
the other three methods in all simulation settings.
4. REAL APPLICATION
We apply the ogClust model to a lung disease transcriptomic dataset with n = 319 patients.
Gene expression data are collected from Gene Expression Omnibus (GEO) GSE47460 and clinical
information obtained from Lung Genomics Research Consortium (https://ltrcpublic.com/).
Majority of patients were diagnosed by two most representative lung disease subtypes: chronic
obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). COPD is a progressive
lung disease caused by the repeated exposure to a noxious agent and is classified by symptoms,
airflow obstruction and exacerbation history. ILD is a loosely defined group of patients characterized
by changes in the interstitium of the lung, causing pulmonary restriction and impaired gas exchange.
Current clinical classification criteria of the subtypes evolve over time and are debatable. They
often fail to accommodate patients with atypical features, who are left unclassified. The current
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criteria also fail to reflect advances of high-throughput mRNA expression techniques to improve
understanding and interpretation of the disease subtypes. In this section, we utilize the standardized
form of a patient’s forced expiratory score (FEV1%prd), a person’s measured FEV1 normalized by
the predicted FEV1 with healthy lung, as the clinical outcome Y to guide the disease subtyping.
Age, gender and BMI are included as covariates X in the ogClust model.
Similar to simulations, we apply ogClust and compare with two existing methods, sparse K-
means and supervised clustering. Data are first preprocessed by conventional procedures following
an earlier publication (Kim et al., 2015). Non-expressed genes (mean expression in the lower 50
percentile) are filtered and top informative genes (genes with the largest variance) are selected
for analysis. Table 2 shows the result when setting the number of subgroups K = 3 (see Figure
S3 for analysis of justifying selection of K), and using the top 500, 1000 and 2000 pre-filtered
genes (by the largest variance) in the comparison. Since, unlike in simulations, the underlying true
class labels Z are unknown, we benchmark the clustering performance in several measures. We
compare the outcome prediction error using RMSE and R2 and evaluate p-value of the association
between subgroups and the FEV1%prd outcome by Kruskal-Wallis test. We also show the number
of selected genes, which has at least one non-zero γˆjk (1 ≤ k ≤ K), used to characterize the
disease subtypes. The result in Table 2 shows that ogClust identifies disease subtypes with better
association with clinical outcome with smaller number of genes compared to sparse K-means and
supervised clustering. For example, when the top 2000 pre-filtered genes are used, ogClust selects
22 genes to define three disease subtypes that explain FEV1%prd outcome with R2 = 0.350 and
association p = 1.84 × 10−57. In contrast, sparse K-means needs 253 genes to reach R2 = 0.055
and p = 5.11× 10−7. Although supervised clustering also aims to detect subtypes associated with
outcome, it only improves slightly from sparse K-means with R2=0.058 and p = 2.11 × 10−8.
Compared with ogClust, ogClust-adHuber better explains outcome with R2 = 0.455, and has
relatively lower association with p = 9.49× 10−24. Figure 4A shows the clinical diagnosis (piechart
above), expression of the selected genes (heatmap in the middle), distribution of outcome (boxplot
below) for each method. For the three clusters identified by ogClust, one cluster is almost purely
COPD (blue bar), one cluster is almost purely ILD (red bar) and one cluster in between with mixed
COPD and ILD (green bar). The result indicates existence of a COPD/ILD intermediate subtype of
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patients that have distinct molecular expression pattern and FEV1%prd clinical outcome. SKM and
SC, however, identify three clusters with more mixed diagnosis of COPD and ILD and are dominated
by non-outcome-related genes. We next evaluate the enriched pathways and canonical functions
using Ingenuity Pathway Analysis (IPA) tool. To account for the randomness of gene selection, we
repeat the analysis in 500 bootstrapped datasets and select the top 200 most frequently selected
genes as our final input gene list for IPA. As shown in Figure 4B, the genes selected by ogClust are
more significantly enriched in pathways associated with immune responses and organismal injury,
while other methods select genes largely irrelevant to lung disease (e.g. cancer and dermatological
diseases).
5. CONCLUSION
In this paper, we propose a unified outcome-guided clustering (ogClust) framework for disease
subtyping from omics data. ogClust links disease subtyping model and outcome association model
through a latent cluster label Z. From extensive simulations and a real data application on lung
disease transcriptomic data, we demonstrate the ability of ogClust to identify outcome associated
clusters (disease subtypes) that are otherwise easily masked by other facets of clinically irrelevant
cluster structure. Additionally, ogClust is immediately applicable to future patients to predict
their disease subtypes. Unlike hard (deterministic) assignment in hierarchical clustering or K-
means, the prediction is a soft assignment with classification probability, reflecting confidence of
subtyping prediction of each patient.
As mentioned in the Introduction section, the concept of outcome-guided clustering is novel in
the field. It involves both supervised and unsupervised components in the framework but differs
from classical clustering or classification problems. It should not be confused with two types of semi-
supervised machine learning, where mixing of labeled and unlabeled data are trained or constrained
prior knowledge is imposed in clustering. To some extent, it is similar to latent class models
in outcome association, but the latter model cannot provide latent class assignment for future
observations, while ogClust model can predict disease subtypes for precision medicine purpose.
In the current ogClust model, omics data G from a single source are used to characterize the
subtype Z and covariates X do not contribute to clustering. Integration of multi-source of data
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Table 2: Comparison of sparse K-means (SKM), supervised clustering (SC), outcome-guided clus-
tering (ogClust), and ogClust with adaptive-Huber loss (ogClust-adHuber) when applied to the
lung disease transcriptomic dataset. We set the number of subgroups K equals 3, top 500, 1000,
and 2000 genes are used. RMSE and R2 measure outcome prediction performance. Kruskal-Wallis
test measures whether outcome is associated with the clusters. Fisher’s exact test measures whether
subgroup label is consistent with the clinical diagnosis.
K Total number Methods RMSE R2 Kruskal-Wallis Genes Fisher’s exact
of genes test selected test
SKM 0.208 0.060 7.28× 10−5 218 1.34× 10−9
3 500 SC 0.203 0.101 1.36× 10−7 70 3.65× 10−24
ogClust 0.189 0.226 7.21× 10−56 33 2.81× 10−41
ogClust-adHuber 0.168 0.386 2.24× 10−47 11 1.12× 10−18
SKM 0.209 0.052 1.79× 10−6 172 1.27× 10−7
3 1000 SC 0.204 0.086 2.31× 10−5 60 4.43× 10−21
ogClust 0.186 0.249 7.62× 10−56 40 8.05× 10−41
ogClust-adHuber 0.161 0.432 1.00× 10−57 25 1.87× 10−31
SKM 0.208 0.055 5.11× 10−7 253 4.16× 10−23
3 2000 SC 0.207 0.058 2.11× 10−8 45 8.52× 10−14
ogClust 0.173 0.350 1.84× 10−57 22 8.56× 10−34
ogClust-adHuber 0.158 0.455 9.49× 10−24 24 5.51× 10−43
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(e.g. multiple transcriptomic studies or a single study with multi-omics data) requires more careful
modeling for each problem setting and will be a future direction.
ogClust parameter estimation is implemented via a modified EM algorithm and thus provides
fast computing for high-dimensional data. In the lung disease example, the model fitting can be
finished in 2.17 minutes using 1 core (Intel Xeon 6130) for n = 319 patients, q = 2000 genes and
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Figure 4: (A) Pie chart of clinical diagnosis (top), heatmap of expression of selected genes (middle),
and boxplot of outcome FEV1%prd (bottom) in each cluster for (a) SKM ,(b) SC, and (c) ogClust.
(B) Enriched pathways and top disease annotations of the selected genes for SKM, SC and ogClust.
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p = 3 covariates. To select tuning parameters K and λ by BIC, multiple runs are necessary. An
R package is freely available on https://github.com/liupeng2117/ogClust, along with all data
and code to reproduce results in this paper.
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